A new prediction model in high-grade glioma used combined radiomics and pathomics to forecast one-year progression. Published in Annals of Clinical and Translational Neurology, the study targets a key clinical decision point: distinguishing patients likely to progress within a year from those who may not. The reported framework integrates imaging-derived features with tissue-based signals (radiomics and pathomics) to generate a more actionable risk estimate than clinical factors alone. In practice, it could help standardize prognostic communication and guide trial stratification. For biotech and translational medicine groups, the signal is that multi-modal pathology-and-imaging analytics are moving into more clinically timed endpoints, aligning model outputs to the time horizons that matter for interventions.